Monovalent vaccines are designed to immunize against a single antigen or a single microorganism, and in some cases, monovalent vaccines may be preferable to produce a strong immune response rapidly. CD BioGlyco has established an advanced and specialized platform to provide scientific assistance to clients in the field of monovalent carbohydrate-based vaccine development.
In 1929, Avery and Goebel proved that the immunogenicity of capsular polysaccharides could be enhanced by coupling to carrier proteins. Unfortunately, this discovery was not taken seriously until Robbins and Schneerson synthesized a glycoconjugate vaccine using HibCPS (poly ribosylribitol phosphate) and DT, which became the first conjugate vaccine licensed for use in children under 2 years of age in the USA in 1987 because of its higher immunogenicity and efficacy in clinical trials. The success of the Hib glycoconjugate vaccines spurred the development of monovalent meningococcal glycoconjugate vaccines using DT or TT as the carrier protein, providing longer immune responses and higher immunity to serogroup C in children under 2 years of age.
Among the 13 meningococcal serogroups, serogroups A, B, C, X, Y and W135, are the most pathogenic strains of all meningococcal infections. To date, Neisseria meningitides vaccines have been developed using natural polysaccharides, glycoconjugates, and outer membrane vesicles (OMP). Currently, in addition to three licensed quadrivalent meningococcal conjugate vaccines against serotypes A, C, Y and W135, three licensed monovalent serogroup C conjugate vaccines and one licensed monovalent serogroup A vaccine (MenAfriVac) apply to all age groups.
Fig.1 Example of the effectiveness of vaccine coverage (serogroup C meningococcal disease). (Tontini, 2020)
CD BioGlyco has been working for many years to develop new and improved methods for synthesizing structurally homogeneous carbohydrates and glycopeptides to help our customers produce carbohydrate-based vaccines. The services we offer include but are not limited to:
Combined with experienced professionals and a world-class scientific research platform, CD BioGlyco is committed to providing customers with high-quality carbohydrate-based monovalent vaccines development services, including the design, synthesis and immune efficacy evaluation of vaccines. If you are interested in our services, please contact us directly for more detailed information.